

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on Apr 17, 2025

APC anti-human ?2-microglobulin

RRID:AB_10641281

Type: Antibody

Proper Citation

(BioLegend Cat# 316312, RRID:AB_10641281)

Antibody Information

URL: http://antibodyregistry.org/AB_10641281

Proper Citation: (BioLegend Cat# 316312, RRID:AB_10641281)

Target Antigen: beta2-microglobulin

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: APC anti-human ?2-microglobulin

Description: This monoclonal targets beta2-microglobulin

Target Organism: human

Clone ID: Clone 2M2

Antibody ID: AB_10641281

Vendor: BioLegend

Catalog Number: 316312

Alternative Catalog Numbers: 316311

Record Creation Time: 20241016T220721+0000

Record Last Update: 20241016T221423+0000

Ratings and Alerts

No rating or validation information has been found for APC anti-human α 2-microglobulin.

No alerts have been found for APC anti-human α 2-microglobulin.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Li YR, et al. (2023) Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design. *iScience*, 26(10), 107952.

She R, et al. (2023) Comparative landscape of genetic dependencies in human and chimpanzee stem cells. *Cell*, 186(14), 2977.

Momayyezi P, et al. (2022) Small Interfering RNA Delivery Into Primary Human Natural Killer Cells for Functional Gene Analyses. *Current protocols*, 2(11), e613.

Chimienti R, et al. (2022) Engineering of immune checkpoints B7-H3 and CD155 enhances immune compatibility of MHC-I-/- iPSCs for α cell replacement. *Cell reports*, 40(13), 111423.

Le TA, et al. (2022) Efficient CRISPR-Cas9-mediated mutagenesis in primary human B cells for identifying plasma cell regulators. *Molecular therapy. Nucleic acids*, 30, 621.

Haideri T, et al. (2022) Robust genome editing via modRNA-based Cas9 or base editor in human pluripotent stem cells. *Cell reports methods*, 2(9), 100290.

Replogle JM, et al. (2022) Maximizing CRISPRi efficacy and accessibility with dual-sgRNA libraries and optimal effectors. *eLife*, 11.

Li YR, et al. (2021) Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy. *Cell reports. Medicine*, 2(11), 100449.

Chung H, et al. (2018) Human ADAR1 Prevents Endogenous RNA from Triggering Translational Shutdown. *Cell*, 172(4), 811.